Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options

Authors

Nicole K. Zagelbaum Ward, From the Department of Rheumatology, Keck School of Medicine/University of Southern California, Los Angeles, CA.
Carlos Linares-Koloffon, Yale Center for Asthma and Airway Disease, Yale University School of Medicine, New Haven, CT.
Alba Posligua, Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Liliya Gandrabur, Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Woo Young Kim, Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Kirk Sperber, Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Amy Wasserman, Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Julia Ash, Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.

Author Type(s)

Faculty

Journal Title

Cardiology in Review

First Page

38

Last Page

43

Document Type

Article

Publication Date

1-1-2022

Department

Medicine

Abstract

Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.

Recommended Citation

Zagelbaum Ward, N. K., Linares-Koloffon, C., Posligua, A., Gandrabur, L., Kim, W. Y., Sperber, K., Wasserman, A., & Ash, J. (2022). Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options. Cardiology in Review, 30 (1), 38-43. https://doi.org/10.1097/CRD.0000000000000358